Stryker is expected to report Q1 2026 revenue of $6.36 billion and EPS of $2.99, with its current price of $327.51 trading significantly below the $421.00 average analyst price target.
Investors are primarily focused on the financial quantification of a March 2026 cyberattack that the company confirmed had a "material impact" on Q1 logistics and manufacturing operations.
Despite these disruptions, management has reaffirmed its full-year organic growth guidance of 8.0% to 9.5%, citing resilient underlying demand. Analysts remain bullish on the long-term outlook, buoyed by strong core orthopedic procedure volumes and the continued global expansion of the Mako robotic surgery platform.